Pacific Biosciences reported 7% year-over-year revenue growth in Q2 2025, totaling $39.8 million, driven primarily by consumables. Although instrument sales dipped slightly due to fewer placements, the company sees growing momentum with its high-throughput Revio and benchtop Vega sequencers, especially in clinical markets. Cost reductions and improved cash burn reflect disciplined execution. The company reports lower net losses and maintains a solid cash position of over $300 million, setting the stage for continued adoption of long-read sequencing technology amid evolving market conditions.